Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
2024年2月9日 - 7:55AM
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or
“MTEM”), a clinical-stage biopharmaceutical company developing
novel therapeutics with potent and differentiated mechanisms of
action for cancer, announced participation in the upcoming
Oppenheimer 34th Annual Healthcare Life Sciences Conference.
Oppenheimer 34rd Annual Healthcare Conference, February
13 – 14
- Format: Virtual Presentation
- Date: Wednesday, February 14, 2024
- Time: 9:20 – 9:50am Eastern Time
- Webcast access: The live-streamed
webcast can be accessed here
Presentation links can be found in the “News and Media” section
of the corporate website.
One-on-one meetings may be scheduled directly with Molecular
Templates.
About Molecular
Templates Molecular Templates is a clinical-stage
biopharmaceutical company focused on the discovery and development
of targeted biologic therapeutics. Our proprietary drug platform
technology, known as engineered toxin bodies, or ETBs, leverages
the resident biology of a genetically engineered form of Shiga-like
Toxin A subunit to create novel therapies with potent and
differentiated mechanisms of action for cancer.
Forward-Looking
Statements This press release contains
forward-looking statements for purposes of the Private Securities
Litigation Reform Act of 1995 (the “Act”). Molecular Templates
disclaims any intent or obligation to update these forward-looking
statements and claims the protection of the Act’s Safe Harbor for
forward-looking statements. All statements, other than statements
of historical facts, included in this press release regarding
strategy, future operations, future financial position, future
revenue, projected expenses, prospects, plans and objectives of
management are forward-looking statements. In addition, when or if
used in this press release, the words “may,” “could,” “should,”
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,”
“predict” and similar expressions and their variants, as they
relate to Molecular Templates may identify forward-looking
statements. Examples of such statements include, but are not
limited to, statements regarding the safety or potential efficacy
of Molecular Templates’ drug or biologic candidates; the expected
participation and presentation at upcoming conferences; and
Molecular Templates’ belief that its proprietary biologic drug
platform technology, or ETBs, provides for a differentiated
mechanism of action for cancer.
Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties. Actual events or
results may differ materially from those discussed in the
forward-looking statements as a result of various factors
including, but not limited to, the uncertainties inherent in the
preclinical and clinical development process, including the fact
that interim results may not be indicative of future results;
whether Molecular Templates’ cash resources, will be sufficient to
fund its continuing operations for the periods and/or trials
anticipated; Molecular Templates’ ability to timely enroll patients
in its clinical trials; the ability of Molecular Templates’ to
protect its intellectual property rights; and legislative,
regulatory, political and economic developments, as well as those
risks identified under the heading “Risk Factors” in Molecular
Templates’ filings with the SEC. There can be no assurance that any
of Molecular Templates’ drug or biologic candidates will be
successfully developed, manufactured, or commercialized, that final
results of clinical trials will be supportive of regulatory
approvals required to market products, or that any of the
forward-looking information provided herein will be proven
accurate. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Molecular Templates
specifically disclaims any obligation to update any forward-looking
statement, whether because of new information, future events or
otherwise.
Contacts: grace.kim@mtem.com
Molecular Templates (NASDAQ:MTEM)
過去 株価チャート
から 11 2024 まで 12 2024
Molecular Templates (NASDAQ:MTEM)
過去 株価チャート
から 12 2023 まで 12 2024